Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05986318 2026-03-09

RESPIRE-ILD

Phase 2 Recruiting

98 enrolled

Thoracic

Lung Neoplasms, Lung Diseases, Interstitial, Radiation Pneumonitis

NCT07442890 2026-03-02

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Phase NA Not yet recruiting

238 enrolled

Thoracic

Lung Neoplasms

NCT07213375 2026-01-07

DEXTER

Phase 2/3 Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06974604 2025-10-24

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Phase 2 Recruiting

60 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT00532155 2025-09-10

VITAL

Phase 3 Completed

913 enrolled 16 charts

Thoracic

Carcinoma, Lung Neoplasms

NCT04209218 2025-07-31

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Phase NA Recruiting

1,988 enrolled

Thoracic

Lung Neoplasms, Postoperative Complications

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04786964 2025-04-02

CONTERNO

Phase 3 Terminated

25 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Clinical Trials

MK-3475-01E

RESPIRE-ILD

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

DEXTER

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

VITAL

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

CONTERNO